Most Read Articles
19 Jun 2019
Acquired immunodeficiency syndrome (AIDS) remains as one of the world’s leading causes of mortality in global public health. Dr Charles Hicks shared his insights into the increasing role of dolutegravir (DTG; Tivicay, GSK) – an integrase strand transfer inhibitor (INSTI) – in HIV therapy during the 4th National AIDS Conference 2018 at Swiss Garden International Hotel and Residences, Kuala Lumpur.
2 days ago
Monotherapy with tenofovir disoproxil fumarate increases virologic response for up to 240 weeks in pretreated patients with hepatitis B virus infection (HBV) who are resistant to entecavir and/or adefovir, a new study has found.
Elvira Manzano, 3 days ago
Long-term treatment with the interleukin-5 receptor alpha-directed cytolytic monoclonal antibody benralizumab led to long-term control of asthma, improvement in pulmonary function, and was safe in patients with severe eosinophilic asthma in the 2-year integrated analysis of the SIROCCO, CALIMA, and ZONDA pivotal studies plus the BORA extension study reported at ATS 2019.
Pearl Toh, 15 hours ago
Patients with rheumatoid arthritis (RA) who maintained their disease remission had a significantly reduced risk of clinical and subclinical atherosclerosis, according to the 3-year follow-up data of the GIRRCS* study presented at EULAR 2019.

Sodium benzoate augments clozapine for schizophrenia

10 Feb 2018
The second generation injection may cost up to HK$5000 per month.

Sodium benzoate appears to augment the effects of clozapine, according to a recent study, which shows that the combination therapy results in significant improvements in symptomatology in clozapine-resistant schizophrenia patients.

The randomized, double-blind, placebo-controlled trial included 60 schizophrenia patients stabilized with clozapine who were randomized to receive one of three add-on treatments: 1 g/day of sodium benzoate (n=20), 2 g/day of sodium benzoate (n=20) or placebo (n=20). Add-on treatment was administered for an additional 60 days.

Both doses of sodium benzoate yielded significantly greater changes from baseline in the Scales for the Assessment of Negative Symptoms (SANS-20) scores relative to placebo at 6 weeks (p=0.029 for 1 g; p=0.031 for 2 g).

In comparison, only the 2-g sodium benzoate treatment resulted in significant 6-week improvements in the Positive and Negative Syndrome Scale (PANSS) scores compared with placebo (p=0.006).

Scores in the quality of life scale were also significantly better in the 2-g sodium benzoate vs placebo group at 6 weeks (p=0.009). No such effect was observed with 1 g of the add-on treatment.

In terms of secondary outcomes, neither 1 g or 2 g of add-on sodium benzoate resulted in significant 6-week improvements in depression, as per the Hamilton rating scale for depression (p=0.729 and p=0.114, respectively), and endpoint improvements in cognitive function (p=0.185 and p=0.930, respectively).

Minimal extrapyramidal syndrome was reported in all three groups both at baseline and at the conclusion of the study.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Psychiatry - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
19 Jun 2019
Acquired immunodeficiency syndrome (AIDS) remains as one of the world’s leading causes of mortality in global public health. Dr Charles Hicks shared his insights into the increasing role of dolutegravir (DTG; Tivicay, GSK) – an integrase strand transfer inhibitor (INSTI) – in HIV therapy during the 4th National AIDS Conference 2018 at Swiss Garden International Hotel and Residences, Kuala Lumpur.
2 days ago
Monotherapy with tenofovir disoproxil fumarate increases virologic response for up to 240 weeks in pretreated patients with hepatitis B virus infection (HBV) who are resistant to entecavir and/or adefovir, a new study has found.
Elvira Manzano, 3 days ago
Long-term treatment with the interleukin-5 receptor alpha-directed cytolytic monoclonal antibody benralizumab led to long-term control of asthma, improvement in pulmonary function, and was safe in patients with severe eosinophilic asthma in the 2-year integrated analysis of the SIROCCO, CALIMA, and ZONDA pivotal studies plus the BORA extension study reported at ATS 2019.
Pearl Toh, 15 hours ago
Patients with rheumatoid arthritis (RA) who maintained their disease remission had a significantly reduced risk of clinical and subclinical atherosclerosis, according to the 3-year follow-up data of the GIRRCS* study presented at EULAR 2019.